Ixazomib for the treatment of multiple myeloma

Proteasome inhibitors

(2015) Beverly A. Teicher et al.   BIOCHEMICAL PHARMACOLOGY

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

(2015) Neeraj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341

(2015) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

(2015) David C. Smith et al.   INVESTIGATIONAL NEW DRUGS

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

(2015) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

(2014) P. G. Richardson et al.   BLOOD

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

(2014) Shaji K Kumar et al.   LANCET ONCOLOGY

In vivo evidence insufficient to conclude that "KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission"

(2013) C. E. Behrendt et al.   BLOOD

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Inhibitors of the Immunoproteasome: Current Status and Future Directions

(2013) Zachary Miller et al.   CURRENT PHARMACEUTICAL DESIGN

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

(2013) Bo Hu et al.   PLoS One

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

(2012) Z. Tian et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Immunoproteasome as a Target in Hematologic Malignancies

(2012) Deborah J. Kuhn et al.   SEMINARS IN HEMATOLOGY

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

(2010) Daisuke Tamura et al.   CANCER SCIENCE

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells

(2009) Azhar R. Hussain et al.   LEUKEMIA & LYMPHOMA

One step at a time: endoplasmic reticulum-associated degradation

(2008) Shruthi S. Vembar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE